Team:Wageningen UR

From 2013.igem.org

(Difference between revisions)

Revision as of 15:07, 4 October 2013

Bricks - Devices - Host
Learn more
A modular approach
Learn more
In vivo diagnostics
Learn more
Generating single cell factories
Learn more
Science is rooted in Society
Harvest the opportunities before they hit you
Learn more
Team
Meet them

Follow @iGemWUR2013

The discovery of secondary metabolites has had a profound influence on the development of human medicines. The production of these secondary metabolites in most cases involves a large backbone enzyme that contains multiple catalytic domains and whose genetics is rether complex. One of our goals is to establish a modular system of domain shuffling to generate a plethora of novel enzymes with new and improved functionalities. The possibilities are endless as there are various different domains from fungi that can be added, removed, reordered, exchanged or even customized in this synthetic biology approach. The production of lovastatin currently is in the fungi Aspergillus terreus, which also produces less desirable toxins. Thus try to transfer the entire lovastatin metabolic pathway from A. terreus into another microorganism like Aspergillus niger is one aspect of our goals. The goals also includs host engineering and biosensor in Aspergillus niger.

Project navigation

             Secondary metabolites
             Lovastatin
             Modeling
             Chromoproteins
             Infrastructure
             Biosensors
             Host engineering
        

Secondary metabolites Toolbox Host engineering Project video

Achievements

Bronze medal

Team registration

Complete Judging form

Team Wiki

Present a poster and a talk at the iGEM Jamboree

Document at least one new standard BioBrick Part or Device used in your project/central to your project and submit this part to the iGEM Registry

Silver medal

Experimentally validate that at least one new BioBrick Part or Device of your own design and construction works as expected

Submit this new part to the iGEM Parts Registry

Your project may have implications for the environment, security, safety and ethics and/or ownership and sharing. Describe one or more ways in which these or other broader implications have been taken into consideration in the design and execution of your project

Gold medal

Help any registered iGEM team from another school or institution by, for example, characterizing a part, debugging a construct, or modeling or simulating their system

Your project may have implications for the environment, security, safety and ethics and/or ownership and sharing. Describe a novel approach that your team has used to help you and others consider these aspects of the design and outcomes of synthetic biology efforts. Please justify its novelty and how this approach might be adapted and scaled for others to use

Human practices

Vitruvian man

iGEM Netherlands

Poster presentation

Discursive psychology

Collaborations

Science café

@@ Line 161: / Line 161: @@
 <div id="wrapper">
          <div class="intro">
-The discovery of secondary metabolites has had a profound influence on the development of human medicines. It was Alexander Fleming who in 1928 discovered the first antibiotic, penicillin, that would conquer some of mankind's most ancient scourges, including syphilis, gangrene and tuberculosis. The production of these secondary metabolites in most cases involves a large backbone enzyme that contains multiple catalytic domains and whose genetics is rether complex. One of our goals is to establish a modular system of domain shuffling to generate a plethora of novel enzymes with new and improved functionalities. The possibilities are endless as there are various different domains from fungi that can be added, removed, reordered, exchanged or even customized in this synthetic biology approach. The production of lovastatin, a drug used in lowering LDL cholesterol for patients suffering from cardiovascular disease, has been chosen as a proof of principle. Currently, it is produced in the fungi Aspergillus terreus, which also produces less desirable toxins. Thus try to transfer the entire lovastatin metabolic pathway from A. terreus into another microorganism like Aspergillus niger is one aspect of our goals. The goals also includs host engineering and biosensor in Aspergillus niger.
+The discovery of secondary metabolites has had a profound influence on the development of human medicines. The production of these secondary metabolites in most cases involves a large backbone enzyme that contains multiple catalytic domains and whose genetics is rether complex. One of our goals is to establish a modular system of domain shuffling to generate a plethora of novel enzymes with new and improved functionalities. The possibilities are endless as there are various different domains from fungi that can be added, removed, reordered, exchanged or even customized in this synthetic biology approach. The production of lovastatin currently is in the fungi Aspergillus terreus, which also produces less desirable toxins. Thus try to transfer the entire lovastatin metabolic pathway from A. terreus into another microorganism like Aspergillus niger is one aspect of our goals. The goals also includs host engineering and biosensor in Aspergillus niger.
          </div>